Inhibitor Therapeutics, Inc. (INTI)
OTCMKTS · Delayed Price · Currency is USD
0.0890
+0.0150 (20.27%)
Sep 4, 2026, 4:00 PM EST
Inhibitor Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.52 | 2.38 | 5.61 | 8.84 | 11.95 | 0.03 |
Cash & Short-Term Investments | 0.52 | 2.38 | 5.61 | 8.84 | 11.95 | 0.03 |
Cash Growth | -86.20% | -57.63% | -36.57% | -26.03% | 38923.13% | -59.20% |
Prepaid Expenses | 0.07 | 0.07 | 0.09 | 0.11 | 0.02 | 0.03 |
Total Current Assets | 0.59 | 2.45 | 5.69 | 8.95 | 11.98 | 0.06 |
Property, Plant & Equipment | 0.05 | 0.06 | - | - | - | - |
Total Assets | 0.64 | 2.51 | 5.69 | 8.95 | 11.98 | 0.06 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.14 | 0.05 | 0.02 | 0.03 | 0.15 | 0.28 |
Accrued Expenses | 0.01 | 0.69 | 0.69 | 0.63 | 0.12 | 0.07 |
Current Portion of Long-Term Debt | - | - | - | - | 0.41 | 0.23 |
Current Portion of Leases | 0.03 | 0.02 | - | - | - | - |
Other Current Liabilities | - | - | - | - | - | 0.1 |
Total Current Liabilities | 0.17 | 0.77 | 0.71 | 0.67 | 0.68 | 0.68 |
Long-Term Leases | 0.02 | 0.04 | - | - | - | - |
Long-Term Unearned Revenue | 3 | 3 | 3 | 3 | 3 | 3 |
Total Liabilities | 3.2 | 3.8 | 3.71 | 3.67 | 3.68 | 3.68 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.04 |
Additional Paid-In Capital | 54.14 | 54.11 | 54.09 | 54.05 | 54.03 | 50.05 |
Retained Earnings | -56.72 | -55.42 | -52.12 | -48.78 | -45.75 | -57.67 |
Total Common Equity | -2.56 | -1.29 | 1.99 | 5.28 | 8.3 | -7.58 |
Shareholders' Equity | -2.56 | -1.29 | 1.99 | 5.28 | 8.3 | -3.62 |
Total Liabilities & Equity | 0.64 | 2.51 | 5.69 | 8.95 | 11.98 | 0.06 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.05 | 0.06 | - | - | 0.41 | 0.23 |
Net Cash (Debt) | 0.47 | 2.31 | 5.61 | 8.84 | 11.54 | -0.2 |
Net Cash Growth | -87.22% | -58.73% | -36.57% | -23.40% | - | - |
Net Cash Per Share | 0.00 | 0.01 | 0.03 | 0.05 | 0.03 | -0.00 |
Filing Date Shares Outstanding | 173.79 | 172.57 | 172.32 | 172.02 | 171.79 | 376.86 |
Total Common Shares Outstanding | 173.79 | 172.57 | 172.32 | 172.02 | 171.79 | 376.86 |
Working Capital | 0.41 | 1.68 | 4.99 | 8.28 | 11.3 | -0.62 |
Book Value Per Share | -0.01 | -0.01 | 0.01 | 0.03 | 0.05 | -0.02 |
Tangible Book Value | -2.56 | -1.29 | 1.99 | 5.28 | 8.3 | -7.58 |
Tangible Book Value Per Share | -0.01 | -0.01 | 0.01 | 0.03 | 0.05 | -0.02 |